Compare Novo Nordisk A/S (NVO) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Clear Secure Inc — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Clear Secure Inc trades at $43.44 (market cap $4.44B). The key difference: Novo Nordisk A/S is far larger — about 37.2× Clear Secure Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Clear Secure Inc for 19 Days on average.
| NVO | YOU | |
|---|---|---|
Market Cap | $165.31B | $4.44B |
Volume | 11,432,838 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $63.98 | $62.36 |
52-Week Low | $35.29 | $29.61 |
Typical Hold Time | 116 Days | 19 Days |
Enterprise Value | $179.56B | $3.59B |
Dividend Yield | 4.71% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Clear Secure (YOU) trades at $43.55, up 2.28% today, with a bullish technical signal despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with $0.49 EPS, and shows robust revenue growth and profitability, including a 66.66% gross margin. Recent news highlights strategic partnerships, such as with CrowdStrike, and positive analyst coverage.
The outlook is positive, driven by accelerating membership growth and expanding margins, but risks include high valuation multiples and potential market volatility. Analysts have a consensus price target of $61.40, suggesting upside, with 44% buy ratings indicating cautious optimism amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
